Understanding Trends and Challenges in the Behavioral Health Sector
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 200: Athlete Mental Health and Physical Conditioning With Dawn Staley
AGG Talks: Healthcare Insights Podcast - Episode 4: What to Do When Insurance Companies Deny Behavioral Health Claims
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 189: Student Mental Health with Dr. Stephanie Irby Coard, UNC Professor
What's the Tea in L&E? Is Your Workplace "Toxic?" Best Practices for Psychological Safety
Addiction and the Recovery Journey for Lawyers | Brian Cuban | Texas Appellate Law Podcast
Employee Assistance Programs & Career Balance – IMS Insights Podcast Episode 60
Mental Health in the Legal Field – IMS Insights Podcast Episode 59
Talking About Mental Health at Work – IMS Insights Podcast Episode 58
#WorkforceWednesday: Mental Health Awareness Month in the Workplace - Employment Law This Week®
Legal’s Mental Health Imperative
Compliance Into The Weeds - Mental Health and Compliance Officers
Responding to Trauma in the Workplace with Katharine Manning, President of Blackbird DC: On Record PR
What Can the Show Severance Teach Us About Work-Life Balance? - Hiring to Firing Podcast
A Slow Burn or a Burn Out: How to Know When You Are Past Your Limits
Taking the Pulse, A Health Care and Life Sciences Podcast | Episode 105: Sara Goldsby, Director, DAODAS
#WorkforceWednesday: Federal Focus on Mental Health, FTC and Noncompetes, Gig Work Risks for Hospitals - Employment Law This Week®
“Walking the Walk” on Lawyer Well-Being | Bree Buchanan
DE Under 3: EEOC & DOJ Technical Guidance for Employer’s AI Use; Upcoming EEOC Hearing; Event for Mental Health in the Workplace
DE Under 3: Best Practices, Webinars & Communication – Straight from Government Agencies
Interest in the potential for psilocybin to be developed as a mental health treatment has continued to grow in recent months, due in part to recent activity by the U.S. Food and Drug Administration (FDA) and Drug Enforcement...more
On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (“MAPS PBC”) announced it has submitted a new drug application (“NDA”) to the FDA for the use of...more
On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the Psychedelic Science 2023 conference in Denver was wrapping up. Touted as the...more
The Struggle is Real - Over 17 million people in the United States are diagnosed with major depressive disorder (MDD). Antidepressants and psychotherapy are the leading forms of treatment; however, antidepressants are not...more